We are live on ! Find out more
AQST icon

Aquestive Therapeutics

60 hedge funds and large institutions have $62M invested in Aquestive Therapeutics in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more call options, than puts

Call options by funds: $592K | Put options by funds: $428K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3.21% less ownership

Funds ownership: 45.91%42.7% (-3.2%)

5% less funds holding

Funds holding: 6360 (-3)

13% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 24

28% less capital invested

Capital invested by funds: $86.3M → $62M (-$24.3M)

52% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 23

Holders
60
Holders Change
-3
Holders Change %
-4.76%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
11
Reduced
23
Closed
24
Calls
$592K
Puts
$428K
Net Calls
+$164K
Net Calls Change
+$430K
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
76
VOYA Investment Management
Georgia
-$52K -10,040 Closed
BBHC
77
Brown Brothers Harriman & Co
New York
-$27 -5,100 Closed
Simplex Trading
78
Simplex Trading
Illinois
-$14.8K -3,703 Closed
Legal & General Group
79
Legal & General Group
United Kingdom
-$11K -2,211 Closed
AIP
80
Ameritas Investment Partners
Nebraska
-$9K -1,755 Closed
Citigroup
81
Citigroup
New York
-$5.25K -1,314 -100%
Fidelity Investments
82
Fidelity Investments
Massachusetts
+$4 +1 New
SB
83
Strategic Blueprint
Georgia
+$36 +9 New

AQST Hedge Fund Activity: Q2 2021 in Review

60 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2021, worth a combined $62M — down 28% from $86.3M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of AQST and 21 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.75M. The largest seller was BlackRock, cutting an estimated $4.02M.

  • 60 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2021, down from 63 in Q1 2021.
  • Funds reported $62M of Aquestive Therapeutics stock for Q2 2021, down 28% quarter-over-quarter.
  • 21 funds opened new Aquestive Therapeutics positions in Q2 2021 and 24 closed out, a net change of -3 holders.
  • The largest Aquestive Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $1.75M added.
  • The largest Aquestive Therapeutics seller in Q2 2021 was BlackRock, an estimated $4.02M sold.

Based on aggregated 13F filings for Q2 2021.